The evolving understanding of risk with calcitonin gene-related peptide monoclonal antibodies based on real-world data: A focus on hypertension and Raynaud phenomenon

Headache. 2021 Sep;61(8):1274-1276. doi: 10.1111/head.14198. Epub 2021 Aug 7.

Authors

Ilana D Breen¹, Aaron R Mangold², Juliana H VanderPluym³

Affiliations

¹ Mayo Clinic Alix School of Medicine, Scottsdale, AZ, USA.
² Dermatology, Mayo Clinic Arizona, Scottsdale, AZ, USA.
³ Neurology, Mayo Clinic Arizona, Scottsdale, AZ, USA.

PMID: 34364313
DOI: 10.1111/head.14198

No abstract available

Keywords: Raynaud phenomenon; adverse effects; calcitonin gene-related peptide; hypertension; monoclonal antibody; risk.

MeSH terms

Adult
Antibodies, Monoclonal / adverse effects
Calcitonin Gene-Related Peptide / immunology
Calcitonin Gene-Related Peptide Receptor Antagonists / adverse effects*
Comorbidity
Female
Humans
Hypertension / chemically induced*
Hypertension / epidemiology
Male
Middle Aged
Migraine Disorders / drug therapy*
Migraine Disorders / epidemiology
Raynaud Disease / chemically induced*
Raynaud Disease / epidemiology
Risk
Symptom Flare Up*

Substances

Antibodies, Monoclonal
Calcitonin Gene-Related Peptide Receptor Antagonists
Calcitonin Gene-Related Peptide